Back

Nordic Nanovector ASA: Invitation to Third Quarter 2019 Results Presentation and Webcast

Oslo, Norway, 13 November 2019

 

Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the third quarter 2019 on Tuesday, 19 November 2019. A presentation by Nordic Nanovector’s senior management team will take place at 8:30am CET at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: AKER

The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2019 from 7:00am CET the same day.

 

For further information, please contact:

 

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: moc.r1575894538otcev1575894538onanc1575894538idron1575894538@ri1575894538

 

Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: moc.n1575894538osreg1575894538orewe1575894538detag1575894538itic@1575894538rotce1575894538vonan1575894538cidro1575894538n1575894538

 

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

 

Further information can be found at www.nordicnanovector.com.

 

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.